Lycera and MSD Collaborate on Autoimmune Therapies - - BioPharm International

ADVERTISEMENT

Lycera and MSD Collaborate on Autoimmune Therapies



The biopharmaceutical company lycera has announced a collaboration agreement with Merck, Sharpe & Dohme (MSD) that will focus on developing and commercialising small-molecule therapies for treating a range of autoimmune diseases.

Under the terms of the agreement, Lycera will receive an upfront payment and research funding, and is also eligible to receive more than $300 million in research, development, regulatory and commercialisation milestone payments. MSD will be responsible for clinical development and will have global marketing and commercialisation rights to any products that may be developed. Lycera will be entitled to royalty payments, and development and sales milestones, on global sales from any products resulting from the collaboration.

The collaboration builds on a previous agreement between the two companies, announced in 2011, targeting the retinoic acid related orphan receptor (RORγt), which is a key transcription factor coordinating the differentiation of T-helper 17 cells and the production of highly pro-inflammatory mediators, such as interleukin-17.

In a statement, Rupert Vessey, senior vice president, global scientific strategy, at Merck Research Laboratories, said, “There are substantial unmet medical needs and opportunities in autoimmune disorders, and new targets representing attractive opportunities that we are very pleased to pursue through our new collaboration with Lycera.”

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate
July 29, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
July 28, 2014
FDA Accepts First Biosimilar Filing
July 24, 2014
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
Author Guidelines

Click here